Almost three years after Northwest Biotherapeutics asked the UK regulator to approve its brain cancer vaccine DCVax-L, its quarterly report says the same thing it has said for months: the application "is in the process of undergoing MHRA review".
No decision date. No hearing date. And the company that is waiting ended September with $725,000 in cash.
The balance sheet
Against that cash, Northwest Bio reported total liabilities of $122.4 million. It lost $28.8 million in the third quarter alone and $41.1 million over nine months.
The stock traded at $0.149 on Wednesday afternoon, up 2.0% on the day.
The filing says there is substantial doubt about the company's ability to continue as a going concern.
How the bills get paid
Mostly with shares. In the first nine months of the year, Northwest Bio issued about 189 million shares to settle and convert debt. Shares outstanding reached 1.81 billion on 10 November, out of 2.6 billion authorised.
On 26 October it took another loan from Streeterville Capital: $5.505 million at 8% interest, with a 10% original issue discount. Repayments start in June 2027, at 110% of each principal instalment. In other words, the company receives less than the face amount and pays back more.
What the board is arguing about
The NWBO board splits the usual way. Longs say approval is close and the loans are a bridge to it. Shorts point to the cash line and the share count.
The filing gives neither side a date. What it gives is a timeline measured in loans: each new note buys time, and each conversion adds shares that dilute whatever an approval would be worth.
The MHRA decides whether DCVax-L gets approved. The balance sheet decides how many shares those holding today will be sharing it with.